Arg(129)- prolactin

arginine replaces glycine at position 129

Also Known As:

prolactin, Arg(129)-; G129R peptide; hPRL-G129R

Networked: 7 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 80400
  - Peptide Hormones: 1347
    - Gonadotropins: 5103
      - Pituitary Gonadotropins: 94
        Prolactin: 11484
        Arg(129)- prolactin: 7
    - Pituitary Hormones: 601
      - Anterior Pituitary Hormones: 187
        Prolactin: 11484
        Arg(129)- prolactin: 7
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Peptide Hormones: 1347
    - Pituitary Hormones: 601
      - Anterior Pituitary Hormones: 187
        Prolactin: 11484
        Arg(129)- prolactin: 7

Experts

1.	Chen, W Y: 3 articles (04/2002 - 12/2000)
2.	Chen, Wen Y: 2 articles (02/2004 - 08/2002)
3.	Peirce, Susan K: 2 articles (02/2004 - 08/2002)
4.	Chen, N Y: 2 articles (04/2002 - 12/2000)
5.	Li, W: 2 articles (04/2002 - 12/2000)
6.	Ramamoorthy, P: 2 articles (01/2001 - 12/2000)
7.	Wagner, T E: 2 articles (01/2001 - 12/2000)
8.	Beck, Michael T: 1 article (08/2002)
9.	Beck, M T: 1 article (04/2002)
10.	Holle, L: 1 article (04/2002)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/01/2001 - "In this study three independent yet related experiments were carried out regarding the effects of hPRL-G129R in breast cancer cells. " 12/01/2000 - "In the present study, we test the hypothesis that the inhibitory effect of hPRL-G129R in breast cancer cells occurs, at least in part, through the inhibition of oncogene STAT3 activation. " 11/02/2023 - "hPRL-G129R, an hPRLR antagonist, has been found to induce apoptosis in breast cancer cells via mechanisms currently unknown. " 04/01/2002 - "Based on these results, we believe that hPRL-G129R can be used to improve the outcome of human breast cancer treatment in the near future." 04/01/2002 - "The inhibitory effects of hPRL-G129R were further confirmed in a second experiment using nude mice bearing MCF-7 human breast cancer xenografts and treated with slow-releasing pellets containing hPRL-G129R. "
2.	Neoplasms (Cancer) 04/01/2002 - "At the end of the 7-week study, it was found that hPRL significantly stimulated the in vivo growth of T-47D xenografts (mean tumor volume, 202 +/- 62 mm(3) as compared to 124 +/- 31 mm(3) in control mice), whereas hPRL-G129R inhibited the tumor growth (mean tumor volume, 79+/-32 mm3). " 11/02/2023 - "Further, we found that increasing concentrations of hPRL-G129R inhibited the nuclear localization of PRLR and the levels of signal transducer and activator of transcription (STAT) 5 in tumor-bearing mice and hPRL-G129R also exerted an antiproliferative effect in vivo. " 11/02/2023 - "Clone formation and transwell migration assays showed that hPRL-G129R inhibited PRL-driven proliferation and migration of tumor cells in vitro. " 04/01/2002 - "In this study, we report the in vivo anti-tumor effects of hPRL-G129R in nude mice bearing human breast cancer xenografts (T-47D and MCF-7). " 04/01/2002 - "In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R."

Related Drugs and Biologics

1.	Prolactin
2.	Caspase 3 (Caspase-3)
3.	Estrogen Receptor Modulators (Antiestrogen)
4.	Messenger RNA (mRNA)
5.	Prolactin Receptors (Prolactin Receptor)
6.	Proteins (Proteins, Gene)
7.	Cisplatin (Platino)
8.	matrigel